Patients diagnosed with advanced renal cell carcinoma, who have received prior treatment with anti-angiogenic agents, now have the option of being treated with the small molecule inhibitor cabozantinib.
Patients diagnosed with advanced renal cell carcinoma (RCC), who have received prior treatment with anti-angiogenic agents, now have the option of being treated with cabozantinib (Cabometyx), following its FDA approval.
A small molecule inhibitor that binds c-Met and VEGFR2, cabozantinib was granted orphan drug designation in 2011. The first approval for the drug was a year later, for the treatment of a rare form of thyroid cancer, but the drug failed to improve outcomes in patients with prostate cancer.
Today’s approval follows the results of the phase 3 METEOR trial that met its primary endpoint of progression-free survival (PFS) in 330 patients diagnosed with advanced RCC. The randomized controlled trial compared cabozantinib with the standard of care therapy, everolimus, which is currently used as second-line for RCC. Cabozantinib treatment resulted in a 42% reduction in the rate of disease progression or death compared with everolimus. Further, a significant advantage in PFS was observed with cabozantinib (7.4 months) compared with everolimus (3.8 months) (HR, 0.58; 95% CI 0.45-0.74, P<.0001).
Most importantly, and significant to today’s approval, was recent data that proved a survival advantage of cabozantinib: median overall survival in the intent-to-treat population was 21.4 months, compared with 16.5 months for patients treated with everolimus (HR, 0.66; 95% CI, 0.53-0.83; P = .0003).
“With today’s announcement, patients with previously treated advanced kidney cancer now have a new option, the first and only approved product demonstrated to help patients live longer while also delaying the progression of their cancer,” said Michael M. Morrissey, PhD, president and CEO of Exelixis, the company that has developed cabozantinib, in a press release. “We are proud to bring new hope to this community, who are looking for more therapies that can help extend lives. Exelixis is committed to making Cabometyx available to patients in need within the next couple weeks.”
Most common adverse events (AEs) associated with the drug include diarrhea, fatigue, nausea, decreased appetite, palmar-plantar erythrodysesthesia syndrome, hypertension, vomiting, weight decreased, and constipation. Serious AEs were reported in 40% of patients, the most common being abdominal pain, pleural effusion, diarrhea, and nausea.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More